Neurology

Tracking Alzheimer’s Biomarkers and Cognitive Changes Over Time

Updated

Abstract

In a sample of 350 cognitively unimpaired individuals, increases in plasma p-tau217 and Aβ PET load were associated with a decline in cognitive function over a 3-year period.

  • Longitudinal increases in plasma p-tau217 concentration were associated with declines in cognitive performance as measured by the modified Preclinical Alzheimer's Cognitive Composite (mPACC).
  • An increase in the CSF p-tau181/Aβ42 ratio was also linked to cognitive decline in the entire sample.
  • In individuals who tested positive for Aβ, an increase in Aβ PET load in specific brain regions correlated with cognitive decline.
  • In Aβ-negative individuals, rising plasma p-tau217 levels and Aβ PET load in frontoparietal regions were associated with cognitive deterioration.
  • The study highlights the potential of combining blood-based and neuroimaging biomarkers to track cognitive changes in individuals at risk for Alzheimer's disease.

Simplified

Full Text

We can’t show the full text here under this license.

what lands in your inbox each week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free